🔥Telegram İfşa

Antibiotic resistance is leaving patients with fewer options🦠 In Science Times, CEO Jonathan Solomon shares how BiomX is advancing phage therapy, a precision approach built to break through bacterial defenses 🔗sciencetimes.com/articles/60524… #PhageTherapy #AntibioticResistance #BiomX

BiomX to Report Q2 2025 Financial Results & Program Updates🦠 Join our live webcast and Q&A on August 13 at 8:00AM ET for key updates on financial performance, pipeline progress, and upcoming milestones. Press Release: ir.biomx.com/news-events/pr… #EarningsCall #PHGE #Biotech #NYSE

📢BiomX Q2 2025 Financial Update Q2 marked key milestones: positive BX211 Ph2 in DFO, Nature Communications publication of BX004 Ph1b/2a showing further ~500-fold bacterial reduction vs placebo, and start of BX004 Ph2b dosing 🔗ir.biomx.com/news-events/pr… #Q2Earnings #PHGE

🔹2 Positive Phase 2 studies 🔹Backed by leading healthcare investors 🔹$215M+ raised, (~$40M non-dilutive funding) 🔹$4B+ global market opportunity 🔹>50% PhDs in leadership 🔹Strong IP & manufacturing Advancing Medicine. Precisely. #PHGE #BiomX #Phage

✨Spotlight on BiomX✨ Next week, Jonathan Solomon (CEO) joins the H.C. Wainwright & Co. Conference, & Edith Kario (VP) presents at DFSG 2025 - Proud to showcase our progress and the promise of phage therapy in chronic infections. Come say hi if you’re there! #PhageTherapy #AMR #ChronicDisease

🌍 World Cystic Fibrosis Day We stand with the CF community. BiomX's BX004 phage therapy targets P. aeruginosa, a major driver of chronic lung infections often resistant to antibiotics New approaches are needed, & phage therapy offers real promise #CysticFibrosis #Biotech #Rare

🔬 Why Phage Cocktails Matter Phage cocktails combine multiple phages to cover diverse strains🦠 If bacteria resist one, others step in, making resistance harder and treatment stronger At BiomX, we design precision phage cocktails to outsmart resistance🎯 #PhageTherapy #Infection

🔬Phage therapy offers a precise way to fight antibiotic-resistant infections Specific to harmful bacteria, sparing the microbiome, and able to adapt as bugs evolve At BiomX, we’re developing precision phage therapies for today’s toughest infections🎯 #PhageTherapy #AMR #Biotech

Phage can be adapted to match new resistant bacteria, turning evolution into an advantage At BiomX, we develop precision phage therapy to fight the toughest infections See more👉biomx.com #PhageTherapy #BacterialResistance #SuperBugs #Biotech #Bacteria

📍BiomX at BIO-Europe 2025 — Vienna | Nov 3–5 We’re excited to join the biotech community in Vienna to advance phage therapy as a precise, natural solution for chronic, antibiotic-resistant infections Connect through the BIO partnering platform or directly to meet in person 🤝

We’re looking forward to joining the cystic fibrosis community this week in Seattle! 📍 North American Cystic Fibrosis Conference (NACFC 2025) - October 22–25 Excited to engage in discussions on advancing phage therapy for CF patients with unmet needs #CysticFibrosis #NACFC2025

Understanding how bacteria defend🦠⚔️ themselves is key to advancing bacteriophage therapy 💡A recent article explores these fascinating bacterial defense systems, a field where BiomX brings deep expertise to designing smarter & precise phage solutions👉 ndtv.com/science/centur…

BiomX develops natural & engineered phage therapies that precisely target bacteria involved in chronic diseases. In an era of rising antibiotic resistance, phage therapy offers a promising new way to address unmet medical needs & fight difficult infections🦠🌍#PhageTherapy #AMR

📢BiomX to Report Q3 2025 Financial Results & Program Updates 🦠 Join our live webcast and Q&A on November 12 at 8:30 AM ET for key updates on financial performance, pipeline progress, and upcoming milestones 🔗Webcast: edge.media-server.com/mmc/p/s6tntmgo #EarningsCall #PHGE #Biotech #NYSE

🌍Among the most pressing challenges today are the bacteria that endanger us all 🧬New Genetic Engineering & Biotechnology News feature explores how phage therapy could help counter these threats 💭BiomX CEO Jonathan Solomon shares insights 👉genengnews.com/topics/infecti… #GlobalHealth #PublicHealth #Bacteria #BiomX

📢 BiomX announces Q3 2025 results & key program updates, highlighting continued progress in advancing phage therapy for patients with unmet needs 🔗Read more: ir.biomx.com/news-releases/… #PHGE #PhageTherapy #Biotech #BiomX #ChronicDiseases #InfectiousDiseases #AntibioticResistance

🦠S. aureus drives many DFI/DFO cases and is one of the hardest pathogens to treat Precision phage therapies offer promising potential to directly target this bacteria🔬✨#DiabeticInfections #PHGE #Wounds #InfectiousDisease #Phage #AMR #PhageTherapy #DrugDevelopment #Innovation

After previously injecting their genetic material into a bacterial cell 🧬, phages replicate using the bacterium’s own machinery. As phages accumulate, the cell eventually bursts💥 releasing new phages that continue the cycle & eliminate bacteria driving infection🦠#Biotech #AMR

Thankful for our patients, partners, and the science behind bacteriophage therapy that continues to inspire our mission to develop targeted solutions for chronic diseases. Wishing everyone a warm and meaningful holiday. #Thanksgiving #Biotech #Bacteriophages #ChronicDiseases #AMR

🧫 Why are chronic diabetic foot infections so hard to treat? Biofilms shield bacteria from antibiotics, & poor blood flow+rising resistance make DFI tough to clear Utilizing phage to target resilient biofilms offers a potential new option where current treatments fall short🦠